Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL

Author(s):

Catherine C. Coombs, MD,Bita Fakhri, MD, MPH

Bita Fakhri, MD, MPH, outlines factors she considers when choosing between fixed-duration and continuous BTK inhibitor therapy and discusses how she approaches treatment discussions with patients.

EP: 1.Patient with Newly Diagnosed CLL with High-Risk Features

Now Viewing

EP: 2.Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL

EP: 3.Navigating Continuous BTKi Therapy for CLL in the 1L Setting

EP: 4.Implications of Real-World Data in the 1L Treatment of High-Risk CLL

EP: 5.Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

EP: 6.Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

EP: 7.Perspectives on Shared Decision-Making in the Treatment of CLL

EP: 8.Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL

EP: 9.Expert Insights for Long-Term Treatment Planning in CLL

EP: 10.Patient with R/R CLL Treated with 2L Venetoclax Therapy

EP: 11.Navigating 2L Treatment Options in CLL

EP: 12.Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications

EP: 13.Management Strategies for BTKi-Related CVAEs in CLL

EP: 14.Updates in CLL Treatment Strategies with Noncovalent BTKis

EP: 15.Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

Video content above is prompted by the following question(s):

What factors do you consider when choosing between fixed-duration and continuous BTK inhibitor therapy?
- How do you weigh the pros and cons of each approach, including treatment logistics and time off therapy?